Lexology July 18, 2024
Pearce IP

On 18 July 2024, Roche announced that FDA has accepted its supplemental BLA for Susvimo®, a refillable ocular implant containing a specialised formulation of ranibizumab, for the treatment of diabetic macular oedema (DME) and diabetic retinopathy (DR).

This follows the FDA’s approval of the relaunch of Susvimo® for nAMD earlier...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA clears 1st cloud-based colonoscopy system
Rejecting a Psychedelic Drug for PTSD Treatment: Why and What’s Next
Advice for the FDA on regulating AI
Highly Anticipated FDA Decision Comes Just in Time for Back-to-School Season
COVID-19, flu and RSV shots—an epidemiologist explains why all three matter this fall

Share This Article